Avience Biomedicals Surges with 27.6% Net Profit Growth and Robust Operational Cash Flow in FY26, Fuels Capex
Avience Biomedicals Limited has reported a strong financial performance for the financial year ended March 31, 2026 (FY26), driven by higher profitability, improved operating cash flows, and increased investments in business expansion. The company’s latest financial results highlight steady operational growth and a strategic focus on strengthening its manufacturing capabilities for future opportunities.
Profit Before Tax Jumps Nearly 28%
Avience Biomedicals reported a Profit Before Tax (PBT) of ₹1,246.58 lakh in FY26, compared with ₹976.88 lakh in FY25, representing a 27.6% year-on-year increase.
The improvement in profitability reflects stronger business performance, better operational efficiency, and effective cost management during the year.
Operating Cash Flow Records Strong Growth
The company also generated significantly higher cash from its core operations.
Net cash generated from operating activities increased to ₹590.62 lakh in FY26, up from ₹339.43 lakh in the previous financial year, marking an impressive 74% growth.
The healthy operating cash flow provides Avience Biomedicals with greater financial flexibility to support future expansion plans and business investments.
Company Invests ₹13.45 Crore in Capacity Expansion
As part of its long-term growth strategy, Avience Biomedicals significantly increased its capital expenditure during FY26.
The company invested ₹1,344.86 lakh (approximately ₹13.45 crore) in the purchase of property, plant and equipment, compared with ₹929.85 lakh invested in FY25.
The higher capital expenditure demonstrates management’s commitment to expanding production capacity, modernizing infrastructure, and supporting future business growth.
Expansion Investments Impact Cash Position
The aggressive investment programme resulted in lower cash balances at the end of the financial year.
Cash and cash equivalents stood at ₹227.47 lakh as of March 31, 2026, compared with ₹421.98 lakh a year earlier. However, the reduction was primarily due to strategic investments aimed at strengthening the company’s long-term growth potential.
Balanced Funding Strategy Supports Growth
To finance its expansion plans, Avience Biomedicals adopted a balanced funding approach.
During FY26, the company raised:
- ₹390.75 lakh through fresh equity issuance
- ₹286.91 lakh through net short-term borrowings
This combination of equity and debt financing has enabled the company to invest in growth while maintaining financial flexibility.